论文部分内容阅读
目的观察探讨美托洛尔(倍他乐克)治疗老年冠心病伴房性早搏临床疗效,总结其应用价值。方法选取我院2009年7月至2011年7月58例年龄在60岁以上的冠心病伴房性早搏的患者,均使用美托洛尔(倍他乐克)治疗,观察其治疗前后静息心电图ST段改变、房性早搏的数量、心率及不良反应。结果使用倍他乐克治疗后,静息心电图ST段改变、房性早搏的数量、心率均有明显改善,与治疗前比较差异有统计学意义(P<0.05),具有统计学意义。治疗期间均无出现泛酸、恶心、呕吐等严重胃肠道反应,也无出现心慌、头痛、血压下降等不良反应。结论美托洛尔(倍他乐克)治疗老年冠心病伴房性早搏临床疗效显著,能够有效改善房性早搏的临床症状,无明显不良反应,尤其适合老年患者使用,安全可靠,值得临床合理推广。
Objective To investigate the clinical efficacy of metoprolol (metoprolol) in the treatment of senile coronary heart disease complicated with atrial premature beats and to summarize its clinical value. Methods From July 2009 to July 2011, 58 patients with coronary heart disease and atrial premature beats who were over 60 years of age in our hospital were treated with metoprolol (metoprolol), and their resting before and after treatment ECG ST segment changes, the number of atrial premature beats, heart rate and adverse reactions. Results After treatment with metoprolol, resting ST segment changes, the number of atrial premature beats and heart rate were significantly improved, with statistical significance (P <0.05) before treatment, with statistical significance. During treatment there was no pantothenic acid, nausea, vomiting and other serious gastrointestinal reactions, no palpitation, headache, blood pressure and other adverse reactions. Conclusion Metoprolol (Betaloc) is effective in treating senile coronary heart disease complicated with atrial premature beats, and it can effectively improve the clinical symptoms of atrial premature beats and has no obvious adverse reactions, especially for elderly patients, which is safe and reliable and deserves to be clinically reasonable Promotion.